Allergan successfully completed its tender offer for all the outstanding shares of Vitae Pharmaceuticals Inc.,a clinical-stage biopharmaceutical company based in Fort Washington, Pennsylvania.
Under the terms of the $639 million deal, and Allergan (NYSE: AGN) paid Vitae stockholders $21 per share.
“The completion of the Vitae acquisition will add highly differentiated development compounds and bolsters our innovative medical dermatology pipeline,” said David Nicholson, chief research and development…
Source: bizjournals.com